Ayurvedic Medicines For Psoriasis: A Comprehensive Review Integrating Agadtantra Perspectives

Abstract

Introduction: Psoriasis is a chronic immune-mediated inflammatory dermatosis involving keratinocyte hyperproliferation and T-cell dysregulation. Ayurveda classifies it under Kushtha, mainly due to Vata–Kapha imbalance with vitiation of Rakta dhatu. Modern science links psoriasis to IL-17/IL-23 axis dysfunction, oxidative stress, microbiome alterations, and environmental triggers. Agadtantra introduces the concept of Dushi Visha, representing low-grade, bio-persistent toxins that parallel chronic inflammatory and immune disturbances. Methodology: This narrative review integrates classical Ayurvedic descriptions, contemporary biomedical literature, and available research on Ayurvedic management of psoriasis. Classical texts, peer-reviewed dermatology articles, and evidence on traditional formulations and marketed Ayurvedic psoriasis preparations were analyzed to develop an integrated understanding of pathogenesis and therapeutic strategies. Results: Analysis indicates overlap between Dushi Visha–induced immune instability and modern mechanisms involving IL-17/IL-23 dysregulation, oxidative stress, and microbiome imbalance. Classical Shodhana therapies—Vamana, Virechana, and Raktamokshana—along with formulations such as Mahatikta Ghrita and Kaishora Guggulu, show potential in reducing inflammation and improving lesion severity. Reports on standardized herbal products suggest benefits in symptom reduction and immune modulation, although data remain limited.Discussion: Ayurvedic and biomedical perspectives converge in viewing psoriasis as a systemic immune-metabolic disorder. The correlation between Dushi Visha and chronic inflammatory mediators supports the rationale for combining detoxification-based therapies with herbal immunomodulators. Despite promising clinical observations, robust evidence is insufficient. Well-designed multi-center clinical trials, phytochemical standardization, and strengthened quality-assurance protocols are essential to validate Ayurvedic psoriasis therapies for global acceptance.

References

1. Lowes MA, Suarez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-55.
2. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA. 2020;323(19):1945-60.
3. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94.
4. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
5. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology and management. Ann Intern Med. 2005;143(10):730-8.
6. Parisi R, et al. Global epidemiology of psoriasis. J Investig Dermatol. 2013;133(2):377-85.
7. Benson JM, et al. IL-23/IL-17 axis in psoriasis therapy. Curr Opin Rheumatol. 2021;33(2):124–130.
8. Raho G, et al. Stress and psoriasis. Dermatology. 2012;224(3):1-7.
9. akeshita J, et al. Comorbidities in psoriasis. J Am Acad Dermatol. 2017;76(3):377 390.
10. Greb JE, et al. Psoriasis pathophysiology. Cell. 2016;165(4):993-1007.
11. Coimbra S, et al. Circulating biomarkers in psoriasis. Arch Dermatol Res. 2012;304:513–522.
12. Naldi L, Griffiths CEM. Long-term safety of psoriasis treatments. Am J Clin Dermatol. 2005;6:1–13.
13. Yiu ZZN, et al. Gut microbiome and psoriasis. Br J Dermatol. 2022;187(3):301-314.
14. Baliwag J, Johnston A. IL-17 in psoriasis. Semin Immunopathol. 2016;38:17–27 .
15. Puig L. Psoriasis therapy review. Drugs. 2017;77(2):131-148.
16. Torres T, Puig L. IL-23 inhibitors in psoriasis. Drugs. 2020;80(4):341-352.
17. Chiricozzi A, et al. Keratinocyte proliferation signals. J Dermatol Sci. 2016;84(3):327-333.
18. Takeshita J. Psoriasis mortality & cardiovascular risk. JAMA Dermatol. 2017;153:1–8.
19. Menter A, et al. Psoriasis treatment guidelines. J Am Acad Dermatol. 2019;80:1029–1072.
20. Villanova F, et al. T cell dysfunction in psoriasis. Immunity. 2014;41(1):131–142.
21. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
22. Lynde CW, et al. Psoriasis: pathophysiology. J Cutan Med Surg. 2014;18:319–326.
23. Coates LC, Helliwell PS. Psoriatic arthritis. Lancet. 2016;387:176–187.
24. Gisondi P, et al. Metabolic syndrome link. J Dermatol Treat. 2020;31(4):319-324.
25. Dowlatshahi EA, et al. Psychological impact. Br J Dermatol. 2014;171:485–492.
26. Krueger J, Feldman S. Psoriasis management. N Engl J Med. 2022;386:1163 1171.
27. Lima EA, et al. Oxidative stress link. Immunol Lett. 2022;243:50–59.
28. Foulkes AC, et al. Neuroimmune factors. Front Immunol. 2019;10:312.
29. Yu Y, et al. Gut-skin axis. Clin Rev Allergy Immunol. 2021;61:300–312.
30. Wang X, et al. Microbiome dysbiosis. Cell Rep Med. 2021;2(9):100304.
31. Acharya YT, Ed. Charaka Samhita. Chaukhambha; 2014.
32. Shastri AD, Ed. Sushruta Samhita. Chaukhambha; 2012.
33. Paradakar HS, Ed. Ashtanga Hridaya. Chaukhambha; 2013.
34. Ayurvedic Pharmacopoeia of India. Govt of India; 2001–2016.
35. Ayurvedic Formulary of India. Ministry of AYUSH; 2003–2010.
36. Sharma PV. Dravyaguna Vijnana. Chaukhambha; 2011.
37. Khare CP. Indian Medicinal Plants. Springer; 2007.
38. Katiyar C, et al. Herbal drug discovery. AYU. 2012;33(1):10–19.
39. Kumar S, et al. Psoralea corylifolia review. Pharmacogn Rev. 2018;12(23):84-90.
40. Mathur M, et al. Wrightia tinctoria review. Int J Pharm Sci Res. 2012;14(2):18-23.
41. Kulkarni YA, et al. Curcumin in dermatology. Indian J Dermatol. 2021;66(3):260 268.
42. Bishayi B, et al. Tinospora cordifolia immunomodulation. Phytother Res. 2002;16: 316–322.
43. Sultana S, et al. Acacia catechu pharmacology. Pak J Pharm Sci. 2011;24:521 527.
44. Rathi B, et al. Rubia cordifolia review. Int J Pharm Sci Res. 2012;3(5):1233–1240.
45. Bafna AR, et al. Albizia lebbeck immunomodulation. Indian J Pharm Sci. 2010;72(3):359–365. 46–61. Product monographs from GMP-certified Ayurvedic manufacturers.
46. Shree Baidyanath Ayurved Bhawan (P) Ltd. Swarna Bhasma product page. Baidyanath. Available from: https://www.baidyanathayurved.com/products/swarna bhasma. Accessed 27 Nov 2025.
47. Sharma S. The role of Swarna Bhasma in treatment – J Ayu Integr Med Sci. Available from: https://jaims.in/jaims/article/view/1410. Accessed 27 Nov 2025.
48. Shree Baidyanath Ayurved Bhawan (P) Ltd. Gandhak Rasayan product page. Baidyanath. Available from: https://www.baidyanath.co/products/gandhak-rasayana- pack-of-5-40-tab-each. Accessed 27 Nov 2025.
49. Nille GC. Safe and effective management of psoriasis through Ayurveda. PubMed Central. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994298/. Accessed 27 Nov 2025.
50. Planet Ayurveda. Abhrak Bhasma (Sahastraputi) product page. Available from: https://store.planetayurveda.com/products/abhrak-bhasma-sahastraputi. Accessed 27 Nov 2025.
51. Agalcha R. Case report: Management of chronic plaque psoriasis using Ayurvedic regimen including Abhrak Bhasma. ScienceDirect. 2025. Available from: https://www.sciencedirect.com/science/article/pii/S0975947624001876. Accessed 27 Nov 2025.
52. Planet Ayurveda. Loha Bhasma product page. Available from: https://store.planetayurveda.com/products/loha-bhasma. Accessed 27 Nov 2025.
53. Baidyanath. Tamra Bhasma product page. Available from: https://www.baidyanath.co.in/tamra-bhasma-pd. Accessed 27 Nov 2025